skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Considerations for Antiretroviral Use in Special Patient Populations

HIV-Infected Adolescents and Young Adults

(Last updated:May 01, 2014; last reviewed:May 01, 2014)

Older children and adolescents now make up the largest percentage of HIV-infected children cared for at pediatric HIV clinics in the United States. The Centers for Disease Control and Prevention (CDC) estimates that 26% of the approximately 50,000 new HIV infections diagnosed in 2010 were among youth 13 to 24 years of age. In this age group, 57% of the infections were among young black/African Americans and 75% among young men who have sex with men (MSM).1 Among youth living with HIV infection in 2010, CDC estimates that almost 60% had undiagnosed infections and were unaware they were HIV-infected.2 Recent trends in HIV/AIDS prevalence reveal that the disproportionate burden of AIDS among racial minorities is even greater among minority youth 13 to 24 years of age (64% to 66% of cases) than among those older than 24 years (48% of cases).3 Furthermore, trends for all HIV diagnoses among adolescents and young adults in 46 states and 5 U.S. dependent areas from 2007 to 2010 decreased or remained stable for all transmission categories except among young MSM. HIV-infected adolescents represent a heterogeneous group in terms of sociodemographics, mode of HIV infection, sexual and substance abuse history, clinical and immunologic status, psychosocial development, and readiness to adhere to medications. Many of these factors may influence decisions concerning when to start antiretroviral therapy (ART) and what antiretroviral (ARV) medications to use.

Most adolescents who acquire HIV are infected through sexual risk behaviors. Many of them are recently infected and unaware of their HIV infection status. Thus, many are in an early stage of HIV infection, which makes them ideal candidates for early interventions, such as prevention counseling and linkage to and engagement in care.4 High grade viremia was reported among a cohort of youth identified as HIV-infected by adolescent HIV specialty clinics in 15 major metropolitan U.S. cities. The mean HIV viral load for the cohort was 94,398 copies/ml; 30% of the youth were not successfully linked to care.5 A study among HIV-infected adolescents and young adults presenting for care identified primary genotypic resistance mutations to ARV medications in up to 18% of the evaluable sample of recently infected youth, as determined by the detuned antibody testing assay strategy that defined recent infection as occurring within 180 days of testing.6 Recently, substantial multiclass resistance was noted in a cohort of behaviorally-infected, treatment-naive youth who were screened for an ARV treatment trial.7 As these youth were naive to all ART, this reflects transmission of resistant virus. This transmission dynamic reflects that a substantial proportion of youth’s sexual partners are likely older and may be more ART experienced; thus, awareness of the importance of baseline resistance testing among recently infected youth naive to ART is imperative.

A limited but increasing number of HIV-infected adolescents are long-term survivors of HIV infection acquired perinatally or in infancy through blood products. Such adolescents are usually heavily ART experienced and may have a unique clinical course that differs from that of adolescents infected later in life.8 Those adolescents infected perinatally or in infancy were often started on ART early in life with mono or dual therapy regimens resulting in incomplete viral suppression and emergence of resistance. If these heavily ART-experienced adolescents harbor resistant virus, optimal ARV regimens should be selected on the basis of the same guiding principles used for heavily ART-experienced adults (see Virologic Failure and Suboptimal Immunogic Response).

Adolescents are developmentally at a difficult crossroad. Their needs for autonomy and independence and their evolving decisional capacity intersect and compete with their concrete thinking processes, risk-taking behaviors, preoccupation with self-image, and need to fit in with their peers. This makes it challenging to attract and sustain adolescents’ focus on maintaining their health, particularly for those with chronic illnesses. These challenges are not specific to any particular transmission mode or stage of disease. Thus, irrespective of disease duration or mode of HIV transmission, every effort must be made to engage and maintain adolescents in care so they can improve and maintain their health for the long term. Adolescents may seek care in several settings including pediatric-focused HIV clinics, adolescent/young adult clinics, and adult-focused clinics.9 Regardless of the setting, expertise in caring for adolescents is critical to creating a supportive environment for engaging youth in care.9,10

Antiretroviral Therapy Considerations in Adolescents

Adult guidelines for ART are usually appropriate for postpubertal adolescents because the clinical course of HIV infection in adolescents who were infected sexually or through injection drug use during adolescence is more similar to that in adults than that in children. Adult guidelines can also be useful for postpubertal youth who were perinatally infected. These patients often have treatment challenges associated with the long-term use of ART that mirror those of ART-experienced adults, such as extensive resistance, complex regimens, and adverse drug effects.

Dosage of medications for HIV infection and opportunistic infections should be prescribed according to Tanner staging of puberty and not solely on the basis of age.11,12 Adolescents in early puberty (i.e., Tanner Stages I and II) should be administered doses on pediatric schedules, whereas those in late puberty (i.e., Tanner Stage V) should follow adult dosing schedules. However, Tanner stage and age are not necessarily directly predictive of drug pharmacokinetics. Because puberty may be delayed in children who were infected with HIV perinatally,13 continued use of pediatric doses in puberty-delayed adolescents can result in medication doses that are higher than the usual adult doses. Because data are not available to predict optimal medication doses for each ARV medication for this group of children, issues such as toxicity, pill or liquid volume burden, adherence, and virologic and immunologic parameters should be considered in determining when to transition from pediatric to adult doses. Youth who are in their growth spurt period (i.e., Tanner Stage III in females and Tanner Stage IV in males) and following adult or pediatric dosing guidelines and adolescents who have transitioned from pediatric to adult doses should be closely monitored for medication efficacy and toxicity. Therapeutic drug monitoring can be considered in each of these selected circumstances to help guide therapy decisions. Pharmacokinetic studies of drugs in youth are needed to better define appropriate dosing. For a more detailed discussion, see Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection.14

Adherence Concerns in Adolescents

HIV-infected adolescents are especially vulnerable to specific adherence problems on the basis of their psychosocial and cognitive developmental trajectory. Comprehensive systems of care are required to serve both the medical and psychosocial needs of HIV-infected adolescents, who are frequently inexperienced with health care systems and who lack health insurance. Recent studies in adolescents infected through risk behaviors and in adolescents infected through perinatal transmission demonstrate that many adolescents in both groups face numerous barriers to adherence.15-17 Compared with adults, these youth have lower rates of viral suppression and higher rates of virologic rebound and loss to follow up.18 Many HIV-infected adolescents face challenges in adhering to medical regimens for reasons that include:

  • Denial and fear of their HIV infection;
  • Misinformation;
  • Distrust of the medical establishment;
  • Fear and lack of belief in the effectiveness of medications;
  • Low self-esteem;
  • Unstructured and chaotic lifestyles;
  • Mood disorders and other mental illness;
  • Lack of familial and social support; 
  • Absence of or inconsistent access to care or health insurance; and
  • Risk of inadvertent parental disclosure of the youth’s HIV infection status if parental health insurance is used.

In selecting treatment regimens for adolescents, clinicians must balance the goal of prescribing a maximally potent ART regimen with realistic assessment of existing and potential support systems to facilitate adherence. Adolescents benefit from reminder systems (e.g., beepers, timers, and pill boxes) that are stylish and/or inconspicuous.19 In a recent randomized controlled study among non-adherent youth 15 to 24 years of age, youth who received cell phone medication reminders demonstrated significantly higher adherence and lower viral loads than youth who did not receive the reminder calls.20 It is important to make medication adherence as user friendly and the least stigmatizing possible for the older child or adolescent. The concrete thought processes of adolescents make it difficult for them to take medications when they are asymptomatic, particularly if the medications have side effects. Adherence to complex regimens is particularly challenging at a time of life when adolescents do not want to be different from their peers.21-23 Directly observed therapy may be considered for selected HIV-infected adolescents such as those with mental illness.24-28 

Difficult Adherence Problems

Because adolescence is characterized by rapid changes in physical maturation, cognitive processes, and life style, predicting long-term adherence in an adolescent can be very challenging. The ability of youth to adhere to therapy needs to be considered as part of therapeutic decision making concerning the risks and benefits of starting treatment. Erratic adherence may result in the loss of future regimens because of the development of resistance mutations. Clinicians who care for HIV-infected adolescents frequently manage youth who, while needing therapy, pose significant concerns regarding their ability to adhere to therapy. In these cases, alternative considerations to initiation of therapy can be the following: 

  1. A short-term deferral of treatment until adherence is more likely or while adherence-related problems are aggressively addressed; 
  2. An adherence testing period in which a placebo (e.g., vitamin pill) is administered; and
  3. The avoidance of any regimens with low genetic resistance barriers. 

Such decisions are ideally individualized to each patient and should be made carefully in context with the individual’s clinical status. For a more detailed discussion on specific therapy and adherence issues for HIV-infected adolescents, see Guidelines for Use of Antiretroviral Agents in Pediatric HIV Infection.14

Special Considerations in Adolescents

Sexually transmitted infections (STIs), in particular human papilloma virus (HPV), should also be addressed in all adolescents. In young MSM, screening for STIs may require sampling from several body sites because oropharyngeal, rectal, and urethral infections may be present in this population.29 For a more detailed discussion on STIs, see the most recent CDC guidelines30 and the adult and pediatric opportunistic infection treatment guidelines on HPV among HIV-infected adolescents.31,32 Family planning counseling, including a discussion of the risks of perinatal transmission of HIV and methods to reduce risks, should be provided to all youth. Providing gynecologic care for HIV-infected female adolescents is especially important. Contraception, including the interaction of specific ARV drugs with hormonal contraceptives, and the potential for pregnancy also may alter choices of ART. As an example, efavirenz (EFV) should be used with caution in females of childbearing age and should only be prescribed after intensive counseling and education about the potential effects on the fetus, the need for close monitoring—including periodic pregnancy testing—and a commitment on the part of the teen to use effective contraception. For a more detailed discussion, see HIV-Infected Women and the Perinatal Guidelines.33

Transitioning Care

Given lifelong infection with HIV and the need for treatment through several stages of growth and development, HIV care programs and providers need flexibility to appropriately transition care for HIV-infected children, adolescents, and young adults. A successful transition requires an awareness of some fundamental differences between many adolescent and adult HIV care models. In most adolescent HIV clinics, care is more teen-centered and multidisciplinary, with primary care highly integrated into HIV care. Teen services, such as sexual and reproductive health, substance abuse treatment, mental health, treatment education, and adherence counseling are all found in one clinic setting. In contrast, some adult HIV clinics may rely more on referral of the patient to separate subspecialty care settings, such as gynecology. Transitioning the care of an emerging young adult includes considerations of areas such as medical insurance; the adolescent’s degree of independence/autonomy and decisional capacity; patient confidentiality; and informed consent. Also, adult clinic settings tend to be larger and can easily intimidate younger, less motivated patients. As an additional complication to this transition, HIV-infected adolescents belong to two epidemiologically distinct subgroups: 

  1. Those perinatally infected—who would likely have more disease burden history, complications, and chronicity; less functional autonomy; greater need for ART; and higher mortality risk—and
  2. Those more recently infected because of high-risk behaviors. 

Thus, these subgroups have unique biomedical and psychosocial considerations and needs.

To maximize the likelihood of a successful transition, interventions to facilitate transition are best implemented early on.34 These include the following: 

  • Developing an individualized transition plan to address comprehensive care needs including medical, psychosocial and financial aspects of transitioning; 
  • Optimizing provider communication between adolescent and adult clinics; 
  • Identifying adult care providers willing to care for adolescents and young adults; 
  • Addressing patient/family resistance caused by lack of information, stigma or disclosure concerns, and differences in practice styles; 
  • Preparing youth for life skills development, including counseling them on the appropriate use of a primary care provider and appointment management, the importance of prompt symptom recognition and reporting, and the importance of self-efficacy in managing medications, insurance, and entitlements; 
  • Identifying an optimal clinic model for a given setting (i.e., simultaneous transition of mental health and/or case management versus a gradual phase-in); 
  • Implementing ongoing evaluation to measure the success of a selected model; 
  • Engaging in regular multidisciplinary case conferences between adult and adolescent care providers;
  • Implementing interventions that may be associated with improved outcomes, such as support groups and mental health consultation; 
  • Incorporating a family planning component into clinical care; and
  • Educating HIV care teams and staff about transitioning. 

Discussions regarding transition should begin early and before the actual transition process.35 Attention to these key areas will likely improve adherence to appointments and avert the potential for a youth to fall through the cracks, as it is commonly referred to in adolescent medicine. For a more detailed discussion on specific topics on transitioning care for adolescents and young adults, see http://www.hivguidelines.org/clinical-guidelines/adolescents/transitioning-hiv-infected-adolescents-into-adult-care/.

References

  1. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report 2012;17(No. 3, part A). Table 5a. June 2012. Available at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed January 6, 2013.
  2. Centers for Disease Control and Prevention. Vital signs: HIV infection, testing, and risk behaviors among youths—United States. MMWR Morb Mortal Wkly Rep. Nov 30 2012;61(47):971-976. Available at http://www.ncbi.nlm.nih.gov/pubmed/23190571.
  3. Centers for Disease Control and Prevention. HIV Surveillance in Adolescents and Young Adults. 2011. Available at http://www.cdc.gov/hiv/pdf/statistics_surveillance_Adolescents.pdf. Accessed January 2, 2014.
  4. Philbin MM, Tanner AE, Duval A, Ellen J, Kapogiannis B, Fortenberry JD. Linking HIV-positive adolescents to care in 15 different clinics across the United States: Creating solutions to address structural barriers for linkage to care. AIDS Care. Jan 2014;26(1):12-19. Available at http://www.ncbi.nlm.nih.gov/pubmed/23777542.
  5. Kapogiannis BF, Ellen J, Xu J, Willard N, DuVal A, Pace J, Loeb J, Bethel J, Wilson C, and the ATN 093 Team, and the Adolescent Trials Network for HIV/AIDS Interventions. The Strategic Multisite Initiative for the Identification, Linkage and Engagement to Care of HIV-Infected Youth (SMILE): Can Treatment As Prevention Work for American Minority Youth? Poster presented at: International AIDS Society Conference; Washington, DC; July 22–27, 2012.
  6. Viani RM, Peralta L, Aldrovandi G, et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis. Dec 1 2006;194(11):1505-1509. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17083034.
  7. Agwu AL, Bethel J, Hightow-Weidman LB, et al. Substantial multiclass transmitted drug resistance and drug-relevant polymorphisms among treatment-naive behaviorally HIV-infected youth. AIDS Patient Care STDS. Apr 2012;26(4):193-196. Available at http://www.ncbi.nlm.nih.gov/pubmed/22563607.
  8. Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. Jun 1 2011;57(2):165-173. Available at http://www.ncbi.nlm.nih.gov/pubmed/21407086.
  9. Tanner AE, Philbin MM, Duval A, et al. "Youth friendly" clinics: Considerations for linking and engaging HIV-infected adolescents into care. AIDS Care. Feb 2014;26(2):199-205. Available at http://www.ncbi.nlm.nih.gov/pubmed/23782040.
  10. New York State Department of Health AIDS Institute. Ambulatory Care of HIV-Infected Adolescents. 2012. Available at http://hivguidelines.org/wp-content/uploads/2012/11/ambulatory-care-of-hiv-infected-adolescents-11-19-2012.pdf. Accessed April 2, 2014.
  11. Rogers A (ed). Pharmacokinetics and pharmacodynamics in adolescents. J Adolesc Health. 1994;15:605-678. 
  12. El-Sadar W, Oleske JM, Agins BD, et al. Evaluation and management of early HIV infection. Clinical Practice Guideline No. 7 (AHCPR Publication No. 94-0572). Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. Rockville, MD; 1994. 
  13. Buchacz K, Rogol AD, Lindsey JC, et al. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection. J Acquir Immune Defic Syndr. 2003;33(1):56-65. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12792356&query_hl=17&itool=pubmed_docsum.
  14. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at
    http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. 
    Accessed January 6, 2014. 
  15. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J, Adolescent Trials Network for HIVAI. Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States. AIDS Patient Care STDS. Feb 2010;24(2):97-104. Available at http://www.ncbi.nlm.nih.gov/pubmed/20059354.
  16. Rudy BJ, Murphy DA, Harris DR, Muenz L, Ellen J, Adolescent Trials Network for HIVAI. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDS. Mar 2009;23(3):185-194. Available at http://www.ncbi.nlm.nih.gov/pubmed/19866536.
  17. MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. AIDS Behav. Jan 2013;17(1):86-93. Available at http://www.ncbi.nlm.nih.gov/pubmed/23142855.
  18. Ryscavage P, Anderson EJ, Sutton SH, Reddy S, Taiwo B. Clinical outcomes of adolescents and young adults in adult HIV care. J Acquir Immune Defic Syndr. Oct 1 2011;58(2):193-197. Available at http://www.ncbi.nlm.nih.gov/pubmed/21826014.
  19. Lyon ME, Trexler C, Akpan-Townsend C, et al. A family group approach to increasing adherence to therapy in HIV-infected youths: results of a pilot project. AIDS Patient Care STDS. Jun 2003;17(6):299-308. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12880493.
  20. Belzar M, Naar-King S. Olson J, Clark, Sarr M, and the Adolescent Trials Network for HIV/AIDS Interventions. A pilot study using cell phone interactions to improve HIV medication adherence in adolescents who have previously failed antiretroviral therapy. Paper presented at: 2013 Society for Adolescent Health and Medicine Annual Meeting; Atlanta, GA; March 13–16, 2013. 
  21. Brooks-Gunn J, Graber JA. Puberty as a biological and social event: implications for research on pharmacology. J Adolesc Health. Dec 1994;15(8):663-671. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7696287.
  22. Kyngas H, Hentinen M, Barlow JH. Adolescents' perceptions of physicians, nurses, parents and friends: help or hindrance in compliance with diabetes self-care? J Adv Nurs. Apr 1998;27(4):760-769. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9578206.
  23. La Greca AM. Peer influences in pediatric chronic illness: an update. J Pediatr Psychol. Dec 1992;17(6):775-784. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1484338.
  24. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. Feb 2001;13(1):27-40. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11177463.
  25. Stenzel MS, McKenzie M, Mitty JA, Flanigan TP. Enhancing adherence to HAART: a pilot program of modified directly observed therapy. AIDS Read. Jun 2001;11(6):317-319. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11449925.
  26. Purdy JB, Freeman AF, Martin SC, et al. Virologic response using directly observed therapy in adolescents with HIV: an adherence tool. J Assoc Nurses AIDS Care. Mar-Apr 2008;19(2):158-165. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18328966.
  27. Garvie PA, Lawford J, Flynn PM, et al. Development of a directly observed therapy adherence intervention for adolescents with human immunodeficiency virus-1: application of focus group methodology to inform design, feasibility, and acceptability. J Adolesc Health. Feb 2009;44(2):124-132. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19167660.
  28. Gaur A, Belzer M, Britto P, et al. Directly observed therapy for non-adherent HIV-infected adolescents - lessons learned, challenges ahead. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections. 2008; Boston, MA.
  29. Vermund SH, Wilson CM, Rogers AS, Partlow C, Moscicki AB. Sexually transmitted infections among HIV infected and HIV uninfected high-risk youth in the REACH study. Reaching for Excellence in Adolescent Care and Health. J Adolesc Health. Sep 2001;29(3 Suppl):49-56. Available at http://www.ncbi.nlm.nih.gov/pubmed/11530303.
  30. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. Dec 17 2010;59(RR-12):1-110. Available at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21160459.
  31. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed January 6, 2014. 
  32. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf. Accessed January 8, 2014. 
  33. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed April 2, 2014. 
  34. Valenzuela JM, Buchanan CL, Radcliffe J, et al. Transition to adult services among behaviorally infected adolescents with HIV—a qualitative study. J Pediatr Psychol. Mar 2011;36(2):134-140. Available at http://www.ncbi.nlm.nih.gov/pubmed/19542198.
  35. Committee On Pediatric AIDS. Transitioning HIV-infected youth into adult health care. Pediatrics. Jul 2013;132(1):192-197. Available at http://www.ncbi.nlm.nih.gov/pubmed/23796739.

Back to Top